

# Orexin Receptor Type 1 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/OEB56706818EEN.html>

Date: April 2020

Pages: 80

Price: US\$ 3,500.00 (Single User License)

ID: OEB56706818EEN

## Abstracts

Orexin Receptor Type 1 - Pipeline Review, H1 2020

### SUMMARY

According to the recently published report 'Orexin Receptor Type 1 - Pipeline Review, H1 2020'; Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide.

The report 'Orexin Receptor Type 1 - Pipeline Review, H1 2020' outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 2, 1, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Binge Eating Disorder, Nicotine Addiction, Insomnia, Addiction, Alcohol Addiction, Obstructive Sleep Apnea, Opioid Use Disorder, Anxiety Disorders, Dementia Associated With Alzheimer's

Disease, Drug Addiction, Narcolepsy, Panic Disorders, Parkinson's Disease, Pathological Gambling, Sleep Disorders and Smoking Cessation.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies  
Involved in Therapeutics Development

Chronos Therapeutics Ltd

Eisai Co Ltd

Eolas Therapeutics Inc

Idorsia Pharmaceutical Ltd

Indivior Plc

Inexia Ltd

Johnson & Johnson

OXonium Therapeutics

Sosei Heptares

Yangtze River Pharmaceutical Group

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles

ACT-539313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-010018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EORA-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INDV-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3215 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecules to Antagonize HCRTR1 for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YZJ-1139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones

Featured News & Press Releases

Apr 21, 2020: Idorsia's insomnia drug daridorexant passes Phase III study

Jan 23, 2020: Eisai: Dayvigo (Lemborexant) approved for treatment of insomnia in Japan

Dec 27, 2019: Pivotal phase 3 study of DAYVIGO (lemborexant) for the treatment of insomnia disorder published in JAMA network open

Dec 23, 2019: U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for treatment of insomnia in adult patients

Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer's Disease (CTAD) conference

Dec 09, 2019: Altasciences to conduct clinical trial for Opioid Use Disorder under NIH funding

Dec 02, 2019: Eisai to present latest data on lemborexant at 12th Clinical Trials on Alzheimer's Disease Conference

Nov 22, 2019: A sleeping pill that doesn't make you sway: a new targeted insomnia treatment

Oct 24, 2019: Trial to test insomnia drug for alcohol use disorder

Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder

Sep 26, 2019: Announcement of National Institutes of Health (NIH) grant award through the NIH helping to end addiction long-term (HEAL) initiative

Sep 19, 2019: Eisai to present latest data on Lemborexant at World Sleep Congress

Jul 11, 2019: Latest data on Eisai's lemborexant to be presented at Alzheimer's Association International Conference (AAIC) 2019

Jun 13, 2019: Efficacy and safety data with Idorsias dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio

Jun 11, 2019: Extensive analyses of phase 3 data for investigational Lemborexant assess efficacy and safety profile for the potential treatment of insomnia in adults

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Chronos Therapeutics Ltd, H1 2020

Pipeline by Eisai Co Ltd, H1 2020

Pipeline by Eolas Therapeutics Inc, H1 2020

Pipeline by Idorsia Pharmaceutical Ltd, H1 2020

Pipeline by Indivior Plc, H1 2020

Pipeline by Inexia Ltd, H1 2020

Pipeline by Johnson & Johnson, H1 2020

Pipeline by OXonium Therapeutics, H1 2020

Pipeline by Sosei Heptares, H1 2020

Pipeline by Yangtze River Pharmaceutical Group, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Chronos Therapeutics Ltd

Eisai Co Ltd

Eolas Therapeutics Inc

Idorsia Pharmaceutical Ltd

Indivior Plc

Inexia Ltd

Johnson & Johnson

OXonium Therapeutics

Sosei Heptares

Yangtze River Pharmaceutical Group

## I would like to order

Product name: Orexin Receptor Type 1 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/OEB56706818EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OEB56706818EEN.html>